We are live on
!
Find out more
BWLSA
Blue Water Life Science Advisors Portfolio holdings
AUM
$159M
1-Year Est. Return
139.66%
This Fund
S&P 500
This Quarter
Est. Return
-38.93%
1 Year Est. Return
+139.66%
3 Year Est. Return
+503.09%
5 Year Est. Return
+228.74%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$116M
(-36%)
Cap. Flow
-$23.1M
Cap. Flow
% of AUM
-10.98%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
16
New
3
Increased
6
Reduced
–
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacific Biosciences
PACB
|
+$30.6M |
| 2 |
Natera
NTRA
|
+$24.4M |
| 3 |
10x Genomics
TXG
|
+$18.5M |
| 4 |
Guardant Health
GH
|
+$18.5M |
| 5 |
CareDx
CDNA
|
+$7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$52.2M |
| 2 |
Bio-Techne
TECH
|
+$28.3M |
| 3 |
Agilent Technologies
A
|
+$26.8M |
| 4 |
Avantor
AVTR
|
+$17.3M |
| 5 |
Danaher
DHR
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$46.9B
| $45.9M | 21.78% |
1,127,981
+405,800
| +56% | +$24.4M |
|
|
2
Guardant Health
GH
$21.9B
| $43.8M | 20.79% |
661,445
+270,500
| +69% | +$18.5M |
|
|
3
CareDx
CDNA
$2.41B
| $37.9M | 17.99% |
1,024,515
+179,545
| +21% | +$7M |
|
|
4
Pacific Biosciences
PACB
$395M
| $24.2M | 11.49% |
+2,660,000
| New | +$30.6M |
|
|
AKYA
5
DELISTED
Akoya BioSciences
AKYA
| $23M | 10.89% |
2,088,668
+377,861
| +22% | +$4.38M |
|
|
6
10x Genomics
TXG
$8.1B
| $16.1M | 7.65% |
+211,917
| New | +$18.5M |
|
|
SLGC
7
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $7.96M | 3.78% |
992,086
+591,098
| +147% | +$5.21M |
|
8
Ginkgo Bioworks
DNA
$519M
| $7.18M | 3.41% |
44,542
+1,297
| +3% | +$252K |
|
|
OLK
9
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $3.72M | 1.76% |
+210,439
| New | +$3.43M |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $983K | 0.47% |
194,686
| – | – |
|
|
11
Agilent Technologies
A
$43.9B
| – | – |
-168,150
| Closed | -$26.8M |
|
|
12
Avantor
AVTR
$9.44B
| – | – |
-410,270
| Closed | -$17.3M |
|
|
13
Danaher
DHR
$149B
| – | – |
-35,419
| Closed | -$10.3M |
|
|
14
Bio-Techne
TECH
$11.3B
| – | – |
-218,844
| Closed | -$28.3M |
|
|
15
Thermo Fisher Scientific
TMO
$227B
| – | – |
-78,300
| Closed | -$52.2M |
|
|
BTTX
16
DELISTED
Better Therapeutics, Inc. Common Stock
BTTX
| – | – |
-100,000
| Closed | -$465K |
|
Similar funds
SFC
ACP
CW
SG
LA
CMMS
JWM
AC
Blue Water Life Science Advisors's Q1 2022 Portfolio in Review
As of Q1 2022, Blue Water Life Science Advisors held 16 positions worth $211M, down 36% from $327M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Blue Water Life Science Advisors withdrew a net $23.1M in Q1 2022, closing 6 positions. Its most notable exit was Thermo Fisher Scientific, an estimated $52.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Blue Water Life Science Advisors opened a new position in Pacific Biosciences worth $24.2M.
- Blue Water Life Science Advisors's largest Q1 2022 buy was Pacific Biosciences: 2,660,000 shares worth $24.2M.
- Blue Water Life Science Advisors added most to Natera in Q1 2022, an estimated $24.4M increase.
- Blue Water Life Science Advisors fully exited Thermo Fisher Scientific in Q1 2022, selling an estimated $52.2M.
- Blue Water Life Science Advisors's ten largest holdings make up 100% of its $211M portfolio in Q1 2022.
- Blue Water Life Science Advisors opened 3 new positions and closed 6 in Q1 2022.
- Blue Water Life Science Advisors's portfolio value fell 36% quarter-over-quarter to $211M.
Based on Blue Water Life Science Advisors's 13F filing for Q1 2022, filed 18 May 2022.